This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2018 Oct 13;392(10155):1284-1286.

doi: 10.1016/S0140-6736(18)32330-4. Epub 2018 Sep 21.

Ustekinumab: a promising new drug for SLE?

Nathalie Costedoat-Chalumeau¹, Frédéric A Houssiau²

Affiliations

Affiliations

¹ AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares, 75014 Paris, France; Université Paris Descartes-Sorbonne Paris Cité, Paris, France; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. Electronic address: nathalie.costedoat@aphp.fr.
² Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Université Catholique de Louvain, Brussels, Belgium.

PMID: 30249508
DOI: 10.1016/S0140-6736(18)32330-4

Comment

Ustekinumab: a promising new drug for SLE?

Nathalie Costedoat-Chalumeau et al. Lancet. 2018.

. 2018 Oct 13;392(10155):1284-1286.

doi: 10.1016/S0140-6736(18)32330-4. Epub 2018 Sep 21.

Authors

Nathalie Costedoat-Chalumeau¹, Frédéric A Houssiau²

Affiliations

¹ AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares, 75014 Paris, France; Université Paris Descartes-Sorbonne Paris Cité, Paris, France; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France. Electronic address: nathalie.costedoat@aphp.fr.
² Service de Rhumatologie, Cliniques Universitaires Saint-Luc, Brussels, Belgium; Pôle de Pathologies Rhumatismales Inflammatoires et Systémiques, Université Catholique de Louvain, Brussels, Belgium.

PMID: 30249508
DOI: 10.1016/S0140-6736(18)32330-4

No abstract available

PubMed Disclaimer

Comment on

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study.
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. van Vollenhoven RF, et al. Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21. Lancet. 2018. PMID: 30249507 Clinical Trial.

Similar articles

A case of psoriasis and systemic lupus erythematous successfully treated with ustekinumab.
Nogueira M, Selores M, Torres T. Nogueira M, et al. Eur J Dermatol. 2021 Jun 1;31(3):429-431. doi: 10.1684/ejd.2021.4072. Eur J Dermatol. 2021. PMID: 34309535 No abstract available.
Comment on "Excellent response to ustekinumab in a 9-year-old girl with severe psoriasis".
Sanchez-Flores X, Carrasquillo OY, Nevares-Pomales OW, Colon-Fontanez F. Sanchez-Flores X, et al. Pediatr Dermatol. 2018 Sep;35(5):701. doi: 10.1111/pde.13589. Pediatr Dermatol. 2018. PMID: 30211466 No abstract available.
Response to ustekinumab in a patient with both severe psoriasis and hypertrophic cutaneous lupus.
Winchester D, Duffin KC, Hansen C. Winchester D, et al. Lupus. 2012 Aug;21(9):1007-10. doi: 10.1177/0961203312441982. Epub 2012 Mar 21. Lupus. 2012. PMID: 22438028
Ustekinumab.
Weber J, Keam SJ. Weber J, et al. BioDrugs. 2009;23(1):53-61. doi: 10.2165/00063030-200923010-00006. BioDrugs. 2009. PMID: 19344192 Review.
New interleukin-23 pathway inhibitors in dermatology: ustekinumab, briakinumab, and secukinumab.
Kurzeja M, Rudnicka L, Olszewska M. Kurzeja M, et al. Am J Clin Dermatol. 2011 Apr 1;12(2):113-25. doi: 10.2165/11538950-000000000-00000. Am J Clin Dermatol. 2011. PMID: 21348542 Review.

See all similar articles

Cited by

Systemic Lupus Erythematosus and Cytokine Storm.
Caricchio R, Gallucci S. Caricchio R, et al. Adv Exp Med Biol. 2024;1448:355-364. doi: 10.1007/978-3-031-59815-9_24. Adv Exp Med Biol. 2024. PMID: 39117826 Review.
Autoreactive B cells in SLE, villains or innocent bystanders?
Hamilton JA, Hsu HC, Mountz JD. Hamilton JA, et al. Immunol Rev. 2019 Nov;292(1):120-138. doi: 10.1111/imr.12815. Epub 2019 Oct 21. Immunol Rev. 2019. PMID: 31631359 Free PMC article. Review.
Immunotherapeutic approaches for systemic lupus erythematosus: early overview and future potential.
Huang H. Huang H. Med Rev (2021). 2023 Oct 10;3(6):452-464. doi: 10.1515/mr-2023-0032. eCollection 2023 Dec. Med Rev (2021). 2023. PMID: 38282801 Free PMC article. Review.
The landscape of systemic lupus erythematosus in Brazil: An expert panel review and recommendations.
Klumb EM, Scheinberg M, Souza VA, Xavier RM, Azevedo VF, McElwee E, Restrepo MR, Monticielo OA. Klumb EM, et al. Lupus. 2021 Sep;30(10):1684-1695. doi: 10.1177/09612033211030008. Epub 2021 Jul 13. Lupus. 2021. PMID: 34255586 Free PMC article. Review.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- ClinicalKey
- Elsevier Science
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Health Information